MedPath
HSA Product

MOFECON 500 FILM-COATED TABLETS 500 MG

Product approved by Health Sciences Authority (SG)

Basic Information

MOFECON 500 FILM-COATED TABLETS 500 MG

TABLET, FILM COATED

Regulatory Information

SIN16010P

September 18, 2020

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XL04AA06

Company Information

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Active Ingredients

Mycophenolate Mofetil

Strength: 500 mg

Detailed Information

Contraindications

**CONTRAINDICATIONS** Mofecon should not be given to: - Patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients shown above – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. - Women of childbearing potential who are not using highly effective contraception. - Women of childbearing potential without providing a pregnancy test result to rule out unintended use in pregnancy. - During pregnancy due to its mutagenic and teratogenic potential. - Women who are breastfeeding.

Indication Information

**INDICATIONS** Mofecon is indicated for: - prophylaxis of acute organ rejection and treatment of refractory organ rejection in patients receiving allogeneic renal transplants. - prophylaxis of acute organ rejection and increased graft and patient survival in patients receiving allogeneic cardiac transplants. - prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants. Mofecon should be used concomitantly with cyclosporin and corticosteroids.

© Copyright 2025. All Rights Reserved by MedPath